U.S. Markets close in 2 hrs 9 mins
  • S&P 500

    4,134.59
    +6.60 (+0.16%)
     
  • Dow 30

    33,607.97
    -137.43 (-0.41%)
     
  • Nasdaq

    13,956.90
    +106.90 (+0.77%)
     
  • Russell 2000

    2,215.37
    -18.42 (-0.82%)
     
  • Crude Oil

    60.09
    +0.39 (+0.65%)
     
  • Gold

    1,746.80
    +14.10 (+0.81%)
     
  • Silver

    25.40
    +0.53 (+2.14%)
     
  • EUR/USD

    1.1943
    +0.0026 (+0.2150%)
     
  • 10-Yr Bond

    1.6250
    -0.0500 (-2.99%)
     
  • Vix

    16.72
    -0.19 (-1.12%)
     
  • GBP/USD

    1.3743
    +0.0001 (+0.0055%)
     
  • USD/JPY

    109.1010
    -0.2750 (-0.2514%)
     
  • BTC-USD

    63,294.86
    +3,176.16 (+5.28%)
     
  • CMC Crypto 200

    1,355.97
    +61.98 (+4.79%)
     
  • FTSE 100

    6,890.49
    +1.37 (+0.02%)
     
  • Nikkei 225

    29,751.61
    +212.88 (+0.72%)
     

Vertex to Present at the J.P. Morgan Healthcare Conference on January 11

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 a.m. ET (6:10 a.m. PT).

The audio portion of management’s remarks can be accessed live through Vertex’s website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company’s website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create medicines for people with serious diseases. The company has multiple approved medicines that treat cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com

(VRTX-WEB)

View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005098/en/

Contacts

Vertex Pharmaceuticals Incorporated
Investors:
Michael Partridge, 617-341-6108
Zach Barber, 617-341-6470
Brenda Eustace, 617-341-6187